Table 1.
Baseline characteristics of patients in the training and test datasets
| Variable | Training | Test | P value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control(n = 112) | MACE(n = 113) | Statistics | P-value | Control(n = 29) | MACE(n = 28) | Statistics | P-value | |||
| Demographic features | ||||||||||
| Male | 70 (62.50%) | 69 (61.10%) | 0.049 | 0.824 | 17 (58.60%) | 18 (64.30%) | 0.193 | 0.661 | 0.959 | |
| Age, years | 60.50 ± 9.31 | 59.97 ± 9.07 | 0.430 | 0.830 | 57.76 ± 9.22 | 59.82 ± 10.70 | 0.597 | 0.597 | 0.588 | |
| BMI, kg/m2 | 26.00(24.00, 28.00) | 26.00(23.00, 27.00) | -0.747 | 0.455 | 25.00(23.50, 27.00) | 25.00(24.00, 27.00) | -0.314 | 0.754 | 0.211 | |
| Cardiovascular risk factors | ||||||||||
| Hypertension | 78 (69.60%) | 78 (69.00%) | 0.010 | 0.920 | 22 (75.90%) | 23 (82.10%) | 0.338 | 0.561 | 0.152 | |
| Hyperlipidemia | 12 (10.70%) | 11 (9.70%) | 0.059 | 0.808 | 2 (6.90%) | 3 (10.70%) | 0.259 | 0.967 | 0.744 | |
| Diabetes | 43 (38.40%) | 47 (41.60%) | 0.240 | 0.624 | 14 (48.30%) | 7 (25.00%) | 3.317 | 0.069 | 0.663 | |
| Smoking | 38 (33.90%) | 37 (32.70%) | 0.036 | 0.850 | 6 (20.7%) | 14 (50.00%) | 5.373 | 0.151 | 0.802 | |
| Medications | ||||||||||
| ß-blocker | 4 (3.60%) | 7 (6.20%) | 0.832 | 0.362 | 2 (6.90%) | 3 (10.70%) | 0.002 | 0.967 | 0.258 | |
| ACE-I/ARB1 | 28 (25.00%) | 29 (25.70%) | 0.013 | 0.909 | 9 (31.10%) | 5 (17.90%) | 1.335 | 0.248 | 0.905 | |
| Ca2+ | 33 (29.50%) | 31 (27.40%) | 0.114 | 0.736 | 7 (24.10%) | 16 (57.10%) | 6.447 | 0.011 | 0.082 | |
| Statin | 12 (10.70%) | 20 (17.70%) | 1.077 | 0.134 | 8 (27.60%) | 5 (17.90%) | 0.766 | 0.381 | 0.300 | |
| Antiplatelet | 12 (11.43%) | 14 (13.33%) | 2.249 | 0.675 | 6 (20.70%) | 4 (14.30%) | 0.404 | 0.525 | 0.529 | |
| Lipids, mmol/l | ||||||||||
| CHOL | 4.26 (2.74,4.93) | 4.81 (3.82,5.68) | -4.397 | < 0.001* | 4.46 (3.63,5.19) | 5.72 (4.31,6.84) | -3.129 | 0.002* | 0.021* | |
| TG | 1.40 (0.97,1.89) | 1.39 (1.04,2.46) | -2.116 | 0.034* | 1.26 (1.03,1.67) | 2.14 (1.71,3.84) | -4.302 | < 0.001* | 0.010* | |
| HDL-C | 1.05 (0.91, 1.25) | 1.08 (0.88, 1.40) | -0.980 | 0.327 | 1.15 (0.85,1.38) | 1.06 (0.88, 1.35) | -0.391 | 0.696 | 0.629 | |
| LDL-C | 2.36 (1.38,2.83) | 2.81 (2.07,3.63) | -4.999 | < 0.001* | 2.73 (2.01,3.10) | 3.24 (2.34,4.14) | -2.259 | 0.024* | 0.041 | |
| Inflammatory markers | ||||||||||
| WBC count, *109/l | 6.63 (5.70, 7.90) | 7.20 (5.65, 8.40) | -1.396 | 0.163 | 6.20 (5.10, 7.86) | 7.35 (6.00, 8.38) | -3.162 | 0.002* | 0.075 | |
| hs-CRP, mg/l | 2.60 (0.90, 4.70) | 3.60 (2.50, 4.65) | -2.277 | 0.023* | 1.80 (0.70, 3.51) | 3.70 (2.75, 4.57) | -2.172 | 0.030* | 0.464 | |
MACE major adverse cardiac event, BMI body mass index, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, Ca2 + calcium channel blocker, CHOL total cholesterol, TG triglycerides, HDL-C high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, WBC white blood cell, hs-CRP high-sensitivity C-reactive protein, UA unstable angina
*indicated P < 0.05 with significance